181 related articles for article (PubMed ID: 15269926)
1. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database.
Seaman HE; de Vries CS; Farmer RD
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):427-36. PubMed ID: 15269926
[TBL] [Abstract][Full Text] [Related]
2. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.
Seaman HE; de Vries CS; Farmer RD
Hum Reprod; 2003 Mar; 18(3):522-6. PubMed ID: 12615818
[TBL] [Abstract][Full Text] [Related]
3. The risk of liver disorders in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested case-control study using the GPRD.
Seaman HE; de Vries CS; Farmer RD
Pharmacoepidemiol Drug Saf; 2003; 12(7):541-50. PubMed ID: 14558177
[TBL] [Abstract][Full Text] [Related]
4. Prescribing of cyproterone acetate/ethinylestradiol in UK general practice: a retrospective descriptive study using The Health Improvement Network.
Cea Soriano L; Asiimwe A; García Rodriguez LA
Contraception; 2017 Mar; 95(3):299-305. PubMed ID: 27769766
[TBL] [Abstract][Full Text] [Related]
5. Differences in the use of combined oral contraceptives amongst women with and without acne.
Seaman HE; de Vries CS; Farmer RD
Hum Reprod; 2003 Mar; 18(3):515-21. PubMed ID: 12615817
[TBL] [Abstract][Full Text] [Related]
6. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation.
Spitzer WO
J Obstet Gynaecol Can; 2003 Dec; 25(12):1011-8. PubMed ID: 14663535
[TBL] [Abstract][Full Text] [Related]
7. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy.
Franks S; Layton A; Glasier A
Hum Reprod; 2008 Feb; 23(2):231-2. PubMed ID: 18083746
[TBL] [Abstract][Full Text] [Related]
8. Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.
Lidegaard Ø
J Obstet Gynaecol Can; 2003 Jul; 25(7):575-7. PubMed ID: 12851669
[TBL] [Abstract][Full Text] [Related]
9. [The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type].
Gollnick H; Albring M; Brill K
Ann Endocrinol (Paris); 1999 Sep; 60(3):157-66. PubMed ID: 10520404
[TBL] [Abstract][Full Text] [Related]
10. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects.
Ruan X; Kubba A; Aguilar A; Mueck AO
Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):183-190. PubMed ID: 28463030
[TBL] [Abstract][Full Text] [Related]
11. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review.
Bitzer J; Römer T; Lopes da Silva Filho A
Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):172-182. PubMed ID: 28447864
[TBL] [Abstract][Full Text] [Related]
12. Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment.
Li Y; Ruan X; Wang H; Li X; Cai G; Du J; Wang L; Zhao Y; Mueck AO
Fertil Steril; 2018 Apr; 109(4):720-727. PubMed ID: 29525688
[TBL] [Abstract][Full Text] [Related]
13. Effect of cyproterone acetate/ethinyl estradiol combination on periodontal status and high-sensitivity C-reactive protein levels in women with polycystic ovary syndrome: a cross-sectional study.
Singhal R; Tewari S; Sharma R; Singhal S; Tanwar N; Sangwan A
Quintessence Int; 2024 Apr; 55(4):274-285. PubMed ID: 38391191
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
Palombo-Kinne E; Schellschmidt I; Schumacher U; Gräser T
Contraception; 2009 Apr; 79(4):282-9. PubMed ID: 19272497
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study.
Karakurt F; Sahin I; Güler S; Demirbas B; Culha C; Serter R; Aral Y; Bavbek N
Adv Ther; 2008 Apr; 25(4):321-8. PubMed ID: 18389188
[TBL] [Abstract][Full Text] [Related]
16. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
Lemay A; Dodin S; Turcot L; Déchêne F; Forest JC
Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
[TBL] [Abstract][Full Text] [Related]
18. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
[TBL] [Abstract][Full Text] [Related]
19. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
Dinger J; Assmann A; Möhner S; Minh TD
J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
[TBL] [Abstract][Full Text] [Related]
20. [Cyproterone acetate].
Borelli C
Hautarzt; 2002 Feb; 53(2):149. PubMed ID: 11963195
[No Abstract] [Full Text] [Related]
[Next] [New Search]
